Company Celltech Group PLC
                  TIDM CCH
                  Headline Offer Update
                  Released 18:12 14 Apr 2003
                  Number 0355K






NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA
OR JAPAN

14 April 2003
CELLTECH GROUP PLC ("CELLTECH")
CASH OFFER FOR OXFORD GLYCOSCIENCES PLC ("OGS")

Further to Celltech's announcement on 11 April 2003 that it had purchased
an aggregate of 26,418,956 OGS Shares, representing approximately 47.17
per cent of the issued share capital of OGS, Celltech announces that it has
today purchased a further 2,351,488 OGS Shares at a price of 182 pence per
share, representing approximately 4.20 per cent. of the issued share
capital of OGS. Celltech has now acquired, subject to settlement of these
share purchases, an aggregate of 28,770,444 OGS Shares (including those
represented by OGS ADSs), representing approximately 51.37 per cent. of
the issued share capital of OGS.

In addition, as at 3:00 p.m. (London time) today, valid acceptances of
Celltech's Offer had been received in respect of 1,425,818 OGS Shares
(including those represented by OGS ADSs), representing approximately
2.55 per cent. of the issued share capital of OGS. Accordingly, and
subject to settlement of the share purchases made on 11 April 2003 and
today, Celltech has now acquired, or received valid acceptances in
respect of, an aggregate of 30,196,262 OGS Shares (including those
represented by OGS ADSs), representing approximately 53.92 per cent.
of the issued share capital of OGS.

Celltech's Offer will become unconditional in all respects as soon as
it is confirmed that sufficient of its share purchases meet the
requirements of the City Code on Takeovers and Mergers for counting
towards the fulfilment of the remaining acceptance condition of the
Offer.

Save as set out above, neither Celltech, nor any person acting or
deemed to be acting in concert with Celltech, owned any OGS Shares on
22 January 2003 (being the business day prior to the commencement of
the offer period), nor have any of such persons acquired or agreed to
acquire any OGS Shares (including OGS Shares represented by OGS ADSs)
during the offer period and no acceptances of the Offer have been
received from any persons acting or deemed to be acting in concert
with Celltech.

A further announcement will be made in due course.

Enquiries:

For further information contact:

      Celltech Group plc
      Telephone: +44 (0)1753 534 655
      Dr Peter Fellner, Chief Executive
      Peter Allen, Chief Financial Officer
      Richard Bungay, Director of Corporate Communications

      JPMorgan
      Telephone: +44 (0)20 7742 4000
      Bernard Taylor, Vice Chairman
      Julian Oakley, Managing Director
      Brunswick London Telephone: +44 (0)20 7404 5959
      Jon Coles
      Fiona Fong
      Brunswick New York Telephone: +1 212 333 3810
      Cindy Leggett-Flynn


Terms defined in the Offer Document have the same meaning when used in
this announcement.

Celltech and JPMorgan, acting on its behalf outside the United States,
are offering to purchase all of the issued and to be issued ordinary
shares of 5 pence each in OGS (including those represented by OGS ADSs)
at a price of 182 pence per OGS Share.

This announcement does not constitute an offer or invitation to purchase
any securities or a solicitation of an offer to buy any securities,
pursuant to the Offer or otherwise. The Offer is being made solely by
the Offer Document and the Acceptance Forms accompanying the Offer
Document, which contain the full terms and conditions of the Offer,
including details of how the Offer may be accepted. Celltech filed
with the SEC a Tender Offer Statement on Schedule TO containing the
Offer Document and other related information on 3 March 2003. Free
copies of those documents are available on the SEC's website at
www.sec.gov. The Offer Document and the Acceptance Forms accompanying
the Offer ocument have been made available to all OGS Securityholders
at no charge to them. OGS Securityholders are advised to read the
Offer Document and the accompanying Acceptance Forms which have been
sent to them because they contain important information. OGS
Securityholders in the United States are also advised to read the
Tender Offer Statement because it contains important information.

Unless otherwise determined by Celltech and permitted by applicable
law and regulation, the Offer (including the Loan Note Alternative) is
not being made, directly or indirectly, in or into, or by use of the
mails of, or by any other means or instrumentality (including, without
limitation, telephonically or electronically) of interstate or foreign
commerce of, or of any facility of a national securities exchange of
Canada, nor is it being made in or into Australia or Japan and the
Offer is not capable of acceptance by any such use, means,
instrumentality or facilities or from within Australia, Canada or
Japan.

Accordingly, unless otherwise determined by Celltech and permitted by
applicable law and regulation, neither copies of this announcement nor
any other documents relating to the Offer have been, or may be, mailed
or otherwise forwarded, distributed or sent in or into Australia, Canada
or Japan and persons receiving such documents (including custodians,
nominees and trustees) must not distribute or send them in, into or
from such jurisdictions.

The Loan Notes to be issued pursuant to the Loan Note Alternative
available under the Offer have not been, and will not be, listed on any
stock exchange and have not been and will not be registered under the US
Securities Act of 1933, as amended or under any relevant securities laws
of any state or other jurisdiction of the United States, or under the
relevant securities laws of Australia, Canada or Japan or any other
jurisdiction. Accordingly, unless an exemption under such relevant laws
is available, Loan Notes may not be offered, sold, re-sold or delivered,
directly or indirectly, in, into or from the United States, Australia,
Canada or Japan or any other jurisdiction in which an offer of Loan
Notes would constitute a violation of relevant laws or require
registration of the Loan Notes, or to or for the account or benefit of
any US Person or esident of Australia, Canada or Japan or any other
such jurisdiction.

THE OFFER WILL REMAIN OPEN FOR ACCEPTANCE DURING THE INITIAL OFFER PERIOD.
THE INITIAL OFFER PERIOD FOR ACCEPTANCES AND WITHDRAWALS WILL EXPIRE ON
THE EARLIER OF (i) THE OFFER BECOMING OR BEING DECLARED UNCONDITIONAL IN
ALL RESPECTS AND (ii) 3:00 P.M. (LONDON TIME), 10:00 A.M. (NEW YORK CITY
TIME), ON 15 APRIL 2003, UNLESS FURTHER EXTENDED TO A LATER CLOSING DATE.
OGS SECURITYHOLDERS WILL HAVE THE RIGHT TO WITHDRAW THEIR ACCEPTANCES OF
THE OFFER UNTIL THE END OF THE INITIAL OFFER PERIOD, BUT NOT DURING THE
SUBSEQUENT OFFER PERIOD.

The Offer is conditional upon valid acceptances being received (and not,
where permitted, being withdrawn) by 3:00 p.m. (London time), 10:00 a.m.
(New York City time) on 15 April 2003, or such later time(s) and/or date(s)
as Celltech may, subject to the City Code and in accordance with the US
Securities Exchange Act of 1934, as amended (the "Exchange Act"), decide
in respect of OGS Shares (including those represented by OGS ADSs) which,
together with OGS Shares (including those OGS Shares represented by OGS
ADSs) acquired or agreed to be acquired before or during the Offer Period,
results in Celltech and any persons acting in concert with Celltech holding
OGS Shares (including OGS Shares represented by OGS ADSs) carrying in
aggregate more than 50 per cent of the voting rights normally exercisable
at a general meeting of OGS, including for this purpose (to the extent, if
any, required by the Panel) any voting rights attaching to any OGS Shares
(including OGS Shares represented by OGS ADSs) that are unconditionally
allotted or issued before the Offer becomes or is declared unconditional
as to acceptances pursuant to the exercise of any outstanding subscription
or conversion rights or otherwise.

Celltech reserves the right (but will not be obliged, other than as may be
required by the City Code or the Exchange Act) at any time or from time to
time to extend further the Offer and, in such event, any decision to extend
the Offer will be publicly announced by 8:00 a.m. (London time) in the
United Kingdom and 8:00 a.m. (New York City time) in the United States on
the day (other than a Saturday or Sunday) following the day on which the
Offer was due to expire and which banks are generally open in London for
normal business. Except with the consent of the Panel, the Initial Offer
Period for acceptances and withdrawals may not extend beyond 1:00 p.m.
(London time), 8:00 a.m. (New York City time), on the day which is 21
days after the release of OGS' preliminary results for the year ended
31 December 2003.

The Directors of Celltech accept responsibility for the information
contained in this announcement, and, to the best of their knowledge and
belief (having taken all reasonable care to ensure such is the case), the
information contained in this announcement is in accordance with the facts
and does not omit anything likely to affect the import of such information.

J.P. Morgan plc, which is regulated in the United Kingdom by the Financial
Services Authority, is acting for Celltech and for no one else in
connection with the Offer and will not be responsible to anyone other than
Celltech for providing the protections afforded to customers of JPMorgan
or for providing advice in relation to the Offer, the contents of the
Offer Document or any transaction or arrangement referred to therein.

OGS has equity securities traded on the London Stock Exchange and NASDAQ.
The Panel wishes to draw the attention of member firms of NASDAQ to
certain UK dealing disclosure requirements during the offer period.

The above disclosure requirements are set out in more detail in Rule 8
of the City Code. In particular, Rule 8 requires public disclosure of
dealings during the offer period by persons who own or control, or who
would as a result of any transaction own or control, one per cent. or
more of any class of relevant securities of the offeree company.
Relevant securities include OGS Shares, OGS ADSs and instruments
convertible into OGS Shares or OGS ADSs. This requirement will apply
until the first closing date or, if this is later, the date when the
Offer becomes or is declared unconditional or lapses.

Disclosure should be made on an appropriate form by no later than 12
noon (London time), 7 a.m. (New York City time) on the business day
following the date of the dealing transaction. These disclosures
should be published through a Regulatory Information Service.

The Panel requests that member firms advise those of their clients who
wish to deal in the relevant securities of OGS, whether in the United
States or in the United Kingdom, that they may be affected by these
requirements. If there is any doubt as to their application the Panel
should be consulted (telephone number: +44 (0) 20 7382 9026, fax number:
+44 (0) 20 7638 1554). This announcement has been approved by J.P.Morgan
plc for the purpose of section 21 of the Financial Services and Markets
Act 2000 only.

END